---
title: "Altimmune jumps 3% as obesity drug hits key trial goal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294080166.md"
description: "Altimmune rises 3% after its obesity drug Pemvidutide met primary endpoints in a Phase 2 trial for alcohol use disorder."
datetime: "2026-07-28T14:11:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294080166.md)
  - [en](https://longbridge.com/en/news/294080166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294080166.md)
---

# Altimmune jumps 3% as obesity drug hits key trial goal

Altimmune(ALT.US) 盘中涨**3.11%**，现报**3.052 美元**。

公司宣布其减肥药物 Pemvidutide 在酒精使用障碍的 II 期临床试验中达到主要终点，显著减少重度饮酒天数并改善客观生物标志物，治疗整体耐受性良好。

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence](https://longbridge.com/en/news/294057380.md)
- [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md)
- [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md)
- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)
- [Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/275558195.md)